The Levels of Apolipoproteins A1 and B in the Blood Serum and Their Ratio in Young Adults with Growth Hormone Deficiency in the Dynamics of Recombinant Growth Hormone Therapy

Main Article Content

O.V. Bolshova
T.O. Tkachova
O.A. Vyshnevska
T.M. Malynovska


Aim of the investigation — to study serum levels of apolipoprotein A1 and B and their ratio in 174 young adults (average age — 22.47 ± 0.30 years) with childhood-onset growth hormone deficiency. Materials and methods. The study involved 174 patients (124 males) aged 19 to 34 years. The follow-up period was up to 36 months. Results. It was found that on the background of the treatment with recombinant growth hormone (rGR), there is a gradual increase in the levels of apolipoprotein A1, a decrease in apolipoprotein B levels and normalization of their ratio in most patients after 6–12 months that reduces cardiovascular risk factors in the future. Conclusions. Against the background of rGR therapy in young adults with childhood-onset growth hormone deficiency, there are significant positive changes in some parameters of the lipid profile, namely — substantial increase in apolipoprotein A1 levels, a decrease in the serum content of apolipoprotein B and apoB/apoA1 ratio.

Article Details

How to Cite
Bolshova, O., T. Tkachova, O. Vyshnevska, and T. Malynovska. “The Levels of Apolipoproteins A1 and B in the Blood Serum and Their Ratio in Young Adults With Growth Hormone Deficiency in the Dynamics of Recombinant Growth Hormone Therapy”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), no. 5.77, Oct. 2016, pp. 39-42, doi:10.22141/2224-0721.5.77.2016.78752.
Original Researches


Zak T., Basiak A., Zubkiewicz-Kucharska A., Noczyńska A. The effect of one year therapy with recombinant human growth hormone (rhGH) on growth velocity, calcium-phosphorus metabolism, bone mineral density and changes in body composition in children with growth hormone deficiency (GHD) // Pediatr. Endocrinol. Diabetes Metab. — 2010. — ​Vol. 16(1). — ​P. 39-43.

Verhelst J., Abs R. Cardiovascular risk factors in hypopituitary GH-deficient adults // Eur. J. Endocrinol. — 2009. — ​Vol. 161. — ​P. 41-49. — ​doi: 10.1530/EJE‑09-0291.

Karavia E.A., Zvintzou E., Petropoulou P.I. et al. HDL quality and functionality: what can proteins and genes predict? // Expert Rev. Cardiovasc. Ther. — 2014. — ​Vol. 12(4). — ​P. 521-532. — ​doi: 10.1586/14779072.2014.896741.

Russell-Jones D.L., Watts G.F., Weissberger A. et al. The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients // Clin. Endocrinol. (Oxf.). — 1994. — ​Vol. 41(3). — ​P. 345-350.

Claessen K.M., Appelman-Dijkstra N.M., Adoptie D.M. et al. Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy // J. Clin. Endocrinol. Metab. — 2012. — ​Nov 15 [Epub ahead of print].

Dominiczak M.H., Caslake M.J. Apolipoproteins: metabolic role and clinical biochemistry applications // Ann. Clin. Biochem. — 2011. — ​Vol. 48. — ​P. 498-515. — ​doi: 10.1258/acb.2011.011111.

Wu J.F., Tang Y.Y., Zeng G.F., Tang C.K. Role of apolipoprotein AI on nascent high-density lipoprotein particle formation // Sheng Li Ke Xue Jin Zhan. — 2014. — ​Vol. 45(2). — ​P. 81-86.

Feldt-Rasmussen U., Wilton P., Jonsson P., KIMS Study Group; KIMS International Board. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults // Growth Horm. IGF Res. — 2004. — ​Vol. 14. — ​P. 51-58.

Gasco V., Prodam F., Grottoli S. et al. Growth hormone therapy in adult growth hormone deficiency: a review of treatment schedules and the evidence for low starting doses // Eur. J. Endocrinol. — 2012. — ​Nov 14 [Epub ahead of print].

Kokshoorn N.E., Biermasz N.R., Roelfsema F. et al. GH replacement therapy in elderly GH-deficient patients: a systematic review // Eur. J. Endocrinol. — 2011. — ​Vol. 164(5). — ​P. 657-665.

Johannsson G.J. What happens when growth hormoneis discontinue dat completion of growth? Metabolic aspects // J. Pediatr. Endocrinol. Metab. — 2000. — ​Vol. 13. — ​P. 1321-1326.

Lanes R., Soros A., Gunczler P. et al. Growth hormone deficiency, low levels of adiponectin, and unfavorable plasma lipid and lipoproteins // J. Pediatr. — 2011. — ​Vol. 149. — ​P. 324-329.

Sahebkar A., Watts G.F. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes // Clin. Ther. — 2013. — ​Vol. 35(8). — ​P. 1082-1098. — ​doi: 10.1016/j.clinthera.2013.06.019.

Tuteja S., Rader D.J. High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm // Clin. Pharmacol. Ther. — 2014. — ​Vol. 96(1). — ​P. 48-56. — ​doi: 10.1038/clpt.2014.79.

Kołtowska-Häggström M., Geffner M.E., Jönsson P. et al. Discontinuation of growth hormone (GH) treatment during the transition phase is an important factor determining the phenotype of young adults with non idiopathic childhood-onset GH deficiency // J. Clin. Endocrinol. Metab. — 2010. — ​Vol. 95(6). — ​P. 2646-2654.

Ahmid M., Fisher V., Graveling A.J. et al. Аn audit of the management of childhood-onset growth hormone deficiency during young adulthood in Scotland // Int. J. Pediatr. Endocrinol. — 2016. — ​Vol. 6.

Sukhanov S., Snarski P., Vaughn C. et al. Insulin-like growth factor I reduces lipid oxidation and foam cell formation via downregulation of 12/15-lipoxygenase // Atherosclerosis. — 2015. — ​Vol. 238(2). — ​P. 313-320. — ​doi: 10.1016/j.atherosclerosis.2014.12.024.

Panayiotou A., Griffin M., Georgiou N. et al. ApoB/ApoA1 ratio and subclinical atherosclerosis // Int. Angiol. — 2008. — ​Vol. 27(1). — ​P. 74-80.

Most read articles by the same author(s)

1 2 > >>